石药集团公告称，仑卡奈单抗注射液在中国获临床试验批准

Group 1 - The core point of the article is that Shiyao Group has received clinical trial approval for Lankanaib monoclonal antibody injection in China [1] Group 2 - The approval marks a significant step for the company in advancing its product pipeline [1] - This development may enhance the company's competitive position in the biopharmaceutical market [1] - The clinical trial approval could lead to potential revenue growth if the product successfully reaches the market [1]